Skip to main content
. 2023 Apr 13;24(8):7233. doi: 10.3390/ijms24087233

Figure 2.

Figure 2

Pathways of irinotecan metabolism in the liver cells ① showing the conversion of inactive form to active SN-38 leading to neutropenia; ② the drug enters via ABC transporters where it is converted to derivatives irinotecan M4, APC, and NPC; ③ the excreted version of irinotecan or SN38G is reconverted to active form SN-38 in intestine and causes GI toxicity.